Tom 15, Nr 1 (2020)
Artykuł przeglądowy
Opublikowany online: 2020-02-27
Wyświetlenia strony
1920
Wyświetlenia/pobrania artykułu
4478
Nowe spojrzenie na leczenie przeciwkrzepliwe u pacjentów z chorobą nowotworową w dobie NOAC
DOI: 10.5603/FC.2020.0005
Folia Cardiologica 2020;15(1):19-26.
Streszczenie
Choroba nowotworowa jest stanem związanym z nadkrzepliwością wymagającą terapii przeciwzakrzepowej. Dotychczas u pacjentów z chorobami onkologicznymi stosowano heparyny i antagonistów witaminy K. Obecnie coraz szerzej stosuje się leki z grupy doustnych antykoagulantów niebędących antagonistami witaminy K (NOAC). Na podstawie aktualnego stanu wiedzy należy stwierdzić, że leki z tej grupy mogą być wyborem w leczeniu przeciwkrzepliwym pacjentów z chorobami onkologicznymi przy zachowaniu pewnej ostrożności, tj. po ocenie ryzyka krwawienia oraz analizie stosunku ryzyka do korzyści leczenia przeciwzakrzepowego, a także interakcji leków onkologicznych z lekami z grupy NOAC.
Słowa kluczowe: choroba nowotworowaleczenie przeciwkrzepliwedoustne antykoagulanty niebędące antagonistami witaminy K
Referencje
- Trousseau A. Phlegmasia alba dolens. In: Trousseau A. ed. Clinique Medicale de l’Hotel Dieu de Paris. Balllier, Paris 1865: 654–712.
- Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007; 62(2): 126–136.
- Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J. 1980; 73(7): 841–843.
- White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005; 165(15): 1782–1787.
- Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer. 2006; 106(4): 923–930.
- Rance A, Emmerich J, Guedj C, et al. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet. 1997; 350(9089): 1448–1449.
- Sutherland DE, Weitz IC, Liebman HA, et al. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003; 72(1): 43–52.
- Lee AYY, Lee A. Epidemiology and management of venous thromboembolism in patients with cancer. Thrombosis Research. 2003; 110(4): 167–172.
- Larsen TB, Nielsen PB, Skjøth F, et al. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One. 2014; 9(12): e114445.
- Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators, EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
- Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 1287–1297.
- Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342–2352.
- Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406–1415.
- Zhang J, Xu J, Zhang W, et al. Quality appraisal of guidelines on cancer-associated thrombosis using AGREE II instrument and analysis of current status of new oral anticoagulants. Clin Appl Thromb Hemost. 2019; 25: 1076029619846562.
- Prandoni P, Lensing A, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10): 3484–3488.
- Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146–153.
- Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119(12): 1062–1072.
- Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II); 53rd ASH Annual Meeting and Exposition. San Diego, December 10–13, 2011.
- Lee AYY, Kamphuisen PW, Meyer G, et al. CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015; 314(7): 677–686.
- Raskob GE, van Es N, Segers A, et al. Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016; 3(8): e379–e387.
- Raskob GE, van Es N, Verhamme P, et al. Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
- CASTA-DIVA. ClinicalTrials.gov Identifier: NCT02746185. https://clinicaltrials.gov/ct2/show/NCT02746185 (January 31, 2018).
- Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients With cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
- Deitcher SR, Kessler CM, Merli G, et al. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12(4): 389–396.
- Carrier M, Abou-Nassar K, Mallick R, et al. AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019; 380(8): 711–719.
- Khorana AA, Soff GA, Kakkar AK, et al. CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019; 380(8): 720–728.
- Gajewski P, Szczeklik A. ed. Interna Szczeklika. Ed. 9. Medycyna Praktyczna, Kraków 2018.
- Ording AG, Horváth-Puhó E, Adelborg K, et al. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med. 2017; 6(6): 1165–1172.
- Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014; 134(6): 1198–1204.
- Lindahl TL, Wallstedt M, Gustafsson KM, et al. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res. 2015; 135(3): 544–547.
- Eikelboom JW, van Ryn J, Reilly P, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373(6): 511–520.
- Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124(14): 1573–1579.
- Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015; 131(1): 82–90.
- Portola Pharmaceuticals. US FDA approves Portola Pharmaceuticals’ Andexxa, first and only antidote for the reversal of factor Xa inhibitors. Published on: May 3, 2018. Accessed on: May 4, 2018.
- Peterson EA, Lee AYY, Lee AYY, et al. Treatment of cancer-associated thrombosis. Blood. 2013; 122(14): 2310–2317.
